| Literature DB >> 33745886 |
Jason Gotlib1, Tracy I George2, Melody C Carter3, K Frank Austen4, Bruce Bochner5, Daniel F Dwyer4, Jonathan J Lyons3, Matthew J Hamilton6, Joseph Butterfield7, Patrizia Bonadonna8, Catherine Weiler7, Stephen J Galli9, Lawrence B Schwartz10, Hanneke Oude Elberink11, Anne Maitland12, Theoharis Theoharides13, Celalettin Ustun14, Hans-Peter Horny15, Alberto Orfao16, Michael Deininger17, Deepti Radia18, Mohamad Jawhar19, Hanneke Kluin-Nelemans20, Dean D Metcalfe3, Michel Arock21, Wolfgang R Sperr22, Peter Valent22, Mariana Castells23, Cem Akin24.
Abstract
The American Initiative in Mast Cell Diseases (AIM) held its inaugural investigator conference at Stanford University School of Medicine in May 2019. The overarching goal of this meeting was to establish a Pan-American organization of physicians and scientists with multidisciplinary expertise in mast cell disease. To serve this unmet need, AIM envisions a network where basic, translational, and clinical researchers could establish collaborations with both academia and biopharma to support the development of new diagnostic methods, enhanced understanding of the biology of mast cells in human health and disease, and the testing of novel therapies. In these AIM proceedings, we highlight selected topics relevant to mast cell biology and provide updates regarding the recently described hereditary alpha-tryptasemia. In addition, we discuss the evaluation and treatment of mast cell activation (syndromes), allergy and anaphylaxis in mast cell disorders, and the clinical and biologic heterogeneity of the more indolent forms of mastocytosis. Because mast cell disorders are relatively rare, AIM hopes to achieve a coordination of scientific efforts not only in the Americas but also in Europe by collaborating with the well-established European Competence Network on Mastocytosis.Entities:
Keywords: American Initiative in Mast Cell Diseases (AIM); European Competence Network on Mastocytosis (ECNM); Systemic mastocytosis; anaphylaxis; hereditary alpha-tryptasemia; mast cell activation syndrome; siglec-8
Mesh:
Year: 2021 PMID: 33745886 PMCID: PMC9521380 DOI: 10.1016/j.jaci.2021.03.008
Source DB: PubMed Journal: J Allergy Clin Immunol ISSN: 0091-6749 Impact factor: 14.290